Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation. Dr ...
Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...
What Is Chronic Lymphocytic Leukemia? Chronic lymphocytic leukemia (CLL) is a cancer that affects a type of white blood cell called a "lymphocyte." Lymphocytes help your body fight infection. They're ...
Hosted on MSN
Exercise could ease symptoms for people with Chronic Lymphocytic Leukaemia, reveals new study
Chronic Lymphocytic Leukaemia (CLL) is the most common adult blood cancer in the western world, and it predominantly affects older adults. Most people are diagnosed after the age of 70, but increasing ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...
Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...
ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results